MARKET

BDRX

BDRX

Biodexa Pharmaceuticals plc
NASDAQ
0.7440
-0.0270
-3.50%
Opening 14:52 07/26 EDT
OPEN
0.7732
PREV CLOSE
0.7710
HIGH
0.7750
LOW
0.7400
VOLUME
244.82K
TURNOVER
0
52 WEEK HIGH
9.74
52 WEEK LOW
0.6700
MARKET CAP
10.80M
P/E (TTM)
-0.0652
1D
5D
1M
3M
1Y
5Y
1D
Biodexa Pharmaceuticals Secures $5M Funding
TipRanks · 3d ago
Biodexa Pharmaceuticals plc: Prospectus [Rule 424(b)(3)]
Press release · 4d ago
Weekly Report: what happened at BDRX last week (0715-0719)?
Weekly Report · 4d ago
Biodexa Pharmaceuticals Unveils Series J Warrant
TipRanks · 07/19 13:28
Biodexa Pharmaceuticals announces pricing of $5M registered direct offering
Biodexa Pharmaceuticals announces pricing of $5M registered direct offering. The gross proceeds from the offering are expected to be approximately $5.0 million. Biodex a Pharmaceuticals PLC (NASDAQ:BDRX) announced the offering of ADSs and warrants.
Seeking Alpha · 07/19 12:52
Biodexa Pharmaceuticals Announces Pricing Of $5M Registered Direct Offering And Concurrent Private Placement
Benzinga · 07/19 12:32
Announces Pricing of $5.0 Million Registered Direct Offering and Concurrent Private Placement
Barchart · 07/19 07:30
How Is The Market Feeling About Biodexa Pharmaceuticals?
Biodexa Pharmaceuticals's short percent of float has fallen 35.68% since its last report. The company has 140 thousand shares sold short, which is 1.55% of its float. Short interest is the number of shares that have been sold short but have not yet been covered.
Benzinga · 07/16 18:45
More
About BDRX
Biodexa Pharmaceuticals PLC is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. Its technologies include Biodexa Pharmaceuticals Q-Sphera, MidaCore and MidaSolve. The Q-Sphera technology focuses on long-acting injectables using proprietary three-dimensional (3D) printing technology that encapsulates medicines into bioresorbable polymer microspheres with precision characteristics. The MidaCore technology platform uses ultra-small gold nanoparticle (GNP) drug conjugates. The MidaSolve Nano Inclusion technology solubilizes molecules that have minimal solubility biological potential of Hydrogen (pH), extending available routes of administration, including direct-to-tumor delivery. Its pipeline includes MTX110, MTD201, MTD211 (Schizophrenia, MDD), MTX223, and MTD217.

Webull offers Biodexa Pharmaceuticals PLC-ADR stock information, including NASDAQ: BDRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BDRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BDRX stock methods without spending real money on the virtual paper trading platform.